Autoantibodies to CCL3 are of low sensitivity and specificity for the diagnosis of type 1 diabetes

详细信息    查看全文

• 作者：Gan Huang (1)
  Xuxu Mo (1)
  Muwen Li (1)
  Yufei Xiang (1)
  Xia Li (1)
  Shuoming Luo (1)
  Zhiguang Zhou (1) zhouzg@hotmail.com
• 关键词：Type 1 diabetes – ; Diagnosis – ; CCL3 – ; Autoantibody – ; Radioimmunoprecipitation assay
• 刊名：Acta Diabetologica
• 出版年：2012
• 出版时间：October 2012
• 年：2012
• 卷：49
• 期：5
• 页码：395-399
• 全文大小：198.4 KB
• 参考文献：1. Lebovitz HE (2010) Adjunct therapy for type 1 diabetes mellitus. Nat Rev Endocrinol 6:326–334
  2. Yang L, Luo S, Huang G et al (2010) The diagnostic value of zinc transporter 8 autoantibody (ZnT8A) for type 1 diabetes in Chinese. Diabetes Metab Res Rev 26:579–584
  3. Ekholm E, Gotts盲ter A, Dahlin LB et al (2012) No signs of progressive beta cell damage during 20 years of prospective follow-up of autoantibody-negative diabetes. Acta Diabetol 49:57–62
  4. Tsirogianni A, Pipi E, Soufleros K (2009) Specificity of islet cell autoantibodies and coexistence with other organ specific autoantibodies in type 1 diabetes mellitus. Autoimmun Rev 8:687–691
  5. Jin P, Huang G, Lin J et al (2011) Epitope analysis of GAD65 autoantibodies in adult-onset type 1 diabetes and latent autoimmune diabetes in adults with thyroid autoimmunity. Acta Diabetol 48:149–155
  6. Kim CS, Song MK, Park JS (2007) The clinical and immunogenetic characteristics of adult-onset type 1 diabetes mellitus in Korea. Acta Diabetol 44:45–54
  7. Huang G, Wang X, Li Z et al (2010) Insulin autoantibody could help to screen latent autoimmune diabetes in adults in phenotypic type 2 diabetes mellitus in Chinese. Acta Diabetol. doi:10.1007/s00592-010-0196-2. Published online 16th May 2010
  8. Manczak M, Jiang S, Orzechowska B et al (2002) Crucial role of CCL3/MIP-1alpha in the recurrence of autoimmune anterior uveitis induced with myelin basic protein in Lewis rats. J Autoimmun 18:259–270
  9. Maghazachi AA (2010) Role of chemokines in the biology of natural killer cells. Curr Top Microbiol Immunol 341:37–58
  10. Cameron MJ, Arreaza GA, Grattan M et al (2000) Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol 165:1102–1110
  11. Lohmann T, Laue S, Nietzschmann U et al (2002) Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes 51:2474–2480
  12. Hanifi-Moghaddam P, Kappler S, Seissler J et al (2006) Altered chemokine levels in individuals at risk of type 1 diabetes mellitus. Diabet Med 23:156–163
  13. Pfleger C, Kaas A, Hansen L et al (2008) Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol 128:57–65
  14. Shehadeh N, Pollack S, Wildbaum G et al (2009) Selective autoantibody production against CCL3 is associated with human type 1 diabetes mellitus and serves as a novel biomarker for its diagnosis. J Immunol 182:8104–8109
  15. Ziegler AG, Mollenhauer U, Achenbach P et al (2011) Anti-CCL3 autoantibodies are not markers of type 1 diabetes when measured by a commercial ELISA method. Diabetologia 54:699–700
  16. The expert committee on the diagnosis and classification of diabetes mellitus (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197
  17. Huang G, Zhou ZG, Peng J et al (2003) Detection of GAD-Ab index in diabetic patients using 35S labeled recombinant human GAD65 antigen. Chin J Nucl Med 23:82–86
  18. Wenzlau JM, Juhl K, Yu L et al (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. PNAS 104:17040–17045
• 作者单位：1. Diabetes Center, 2nd Xiangya Hospital, Institute of Metabolism and Endocrinology, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, 410011 Hunan, China
• ISSN：1432-5233

文摘

Type 1 diabetes (T1D) is a T cell–dependent tissue-specific autoimmune disease, characterized by the selective destruction of the β cells of the pancreatic islets of Langerhans. Recently, contradictory findings have been reported about the relationship of autoantibodies to CC chemokine 3 (CCL3) and T1D, which need to be confirmed by more investigations in larger cohorts. The aim of our research was to investigate whether autoantibodies to CCL3 are useful markers for T1D in a large cohort of Chinese patients. We analyzed autoantibodies to CCL3, glutamic acid decarboxylase(GADA), insulinoma-associated protein-2 (IA-2A), and zinc transporter-8 (ZnT8A) by a radioimmunoprecipitation assay in 290 T1D subjects, 200 subjects with type 2 diabetes (T2D), 210 subjects with other diseases, and 178 healthy control subjects. Results showed that the frequencies of autoantibodies to CCL3 in subjects with T1D, T2D, and healthy control subjects were similar [3.10% (9/290), 2.50% (5/200), and 0.56% (1/178), respectively, P = 0.189]. Autoantibodies to CCL3 were not significantly different between T1D patients with or without GADA, IA-2A, or ZnT8A antibodies (2.7% vs. 3.9%, P = 0.725). In contrast, patients with systemic lupus erythematosus and rheumatoid arthritis showed higher positivity for autoantibodies to CCL3 than healthy control subjects [15.6% (5/32) and 12.5% (8/64) vs. 0.56% (1/178), all P = 0.000], and higher titer of autoantibodies to CCL3 than T1D patients (median 0.9633 and 0.4095 vs. 0.0873, P = 0.012 and P = 0.034, respectively). We conclude that autoantibodies to CCL3 are of low sensitivity and specificity for T1D and cannot be used in the diagnosis of T1D.